We found that patients overexpressing HER-2 (luminalHer2+ and HER-2+) and TNBC subtypes were more frequently in grade 3 and T3, and those overexpressing the HER-2+ subtype were more likely to have involvement of nodes, suggesting that these patients who are borderline candidates for breast conservation as a result of a large tumor size relative to the breast size would particularly likely benefit from neoadjuvant therapy that includes trastuzumab. Here, ERBB2 is linked to neoplasm.